Plain-English translation of NCT07481734 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a synthetic medication that works by boosting your body's natural growth hormone production. Researchers believe this medication may help reduce the amount of fat stored in your liver and improve your metabolic health. Past studies have shown promise, and this new trial will confirm whether it works safely and effectively over one year.
Fatty liver disease is very common and can get worse over time, but there are few medications available that directly tackle the problem. This medication offers a new approach by targeting how your body handles fat, potentially helping prevent liver damage and improving overall metabolic health.
You likely qualify if…
You likely don't qualify if…
You will give yourself a daily injection under your skin for one year. You'll visit the clinic at baseline and then at weeks 4, 12, 24, 36, and 52, with an additional safety check at week 56. During these visits, you'll have blood tests, special imaging of your liver (MRI scans at baseline, week 24, and week 52), and an ultrasound-like test called FibroScan to check for scarring. You have the option to participate in a sub-study involving a liver biopsy if you wish.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China